

ZEPOSIA 360 Support™ can facilitate baseline assessment assistance by providing support to eligible commercially insured patients.

Baseline Assessments

Prior to First Dose

- › **Electrocardiogram (ECG) to detect preexisting conduction abnormalities**
- › **Blood work (within the past 6 months)**
 - Complete blood count (CBC), including lymphocyte count
 - Transaminase and bilirubin levels
- › **Determine varicella zoster virus (VZV) history and vaccination status^a and evaluate medication history**

Periodically obtain transaminase and total bilirubin levels.^b

Before or Shortly After Initiation

- › **Ophthalmic evaluation** of the fundus, including the macula^c

- › **Skin examination^d**

Check to see if your patients recently completed, or plan to have, an annual skin or eye exam to satisfy these requirements.

Periodically monitor for changes in vision^c and suspicious skin lesions.^d

These assessments are not intended to make suggestions about the efficacy, safety, or indication of use for the product. For complete ZEPOSIA 360 Support™ terms and conditions, please see www.zeposia.com/terms-conditions.

^aVZV vaccination of antibody-negative patients is recommended prior to commencing treatment. Without documentation of VZV/chicken pox or documentation of a full course of vaccination, test for antibodies. If live attenuated immunizations are required, administer at least 1 month prior to initiation.

^bDuring treatment and until two months after discontinuation.

^cSIP receptor modulators, including ZEPOSIA, have been associated with an increased risk of macular edema. Perform an examination of the fundus, including the macula, periodically while on therapy and any time there is a change in vision.

^dAlso obtain a skin examination periodically during treatment, particularly for patients with risk factors for skin cancer. Providers and patients are advised to monitor for suspicious skin lesions, which should be promptly evaluated if observed.

Two options for patients to receive baseline assessments:



In-home assessments



Healthcare provider (HCP) office assessments

Affordability Matters

Eligible, commercially insured patients may receive assistance with reimbursement for out-of-pocket costs for assessments listed above.

Please see [full Prescribing Information and Medication Guide](#) at www.ZEPOSIAhcp.com.

In-home Assessments


All in-home assessments will need to be completed prior to initiation



HCP requests in-home assessments for patient through **covermyeds®** portal or by checking box on Start Form

May include: ECG, blood work, and ophthalmic evaluation

Note: Skin exams are not available in-home and should be scheduled separately with an HCP.



Support Coordinator^a outreach to patient to schedule appointment

Ensure patient has **1-833-ZEPOSIA** (1-833-937-6742) saved in phone contacts to recognize number



Licensed HCP conducts baseline assessments in patient's home

Results sent to ZEPOSIA 360 Support™ and to the HCP office



HCP provides appropriate clearance for patient to begin treatment

Clearance can be provided through **covermyeds®** portal or by faxing **clearance form** to **1-833-727-7701**

The patient's insurance is not billed for in-home assessments and the patient is not responsible for any out-of-pocket costs.

Skin exams are not available in-home and can be scheduled separately.

Eligible, commercially insured patients may receive assistance with skin exam out-of-pocket costs through the ZEPOSIA 360 Support™ program.

Please discuss reimbursement options with a Support Coordinator.^a

^aZEPOSIA Support Coordinators can provide general information about ZEPOSIA 360 Support™ but cannot provide medical advice.

For additional information and complete terms and conditions for the services listed above, please see www.zeposia.com/terms-conditions.

Please see [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.



HCP office and patient schedule appointments for administering baseline assessments

Assessments include:

- Initial blood work, ECG screening
- Eye, skin exam
- VZV, if required



HCP administers assessments in-office

Claims are submitted to the patient's insurance



Patient collects all receipts related to costs incurred including explanation of benefits from their insurance

Receipts may include:

- Initial blood test, ECG screening
- Eye and skin exam (when administered)



Patient contacts ZEPOSIA 360 SUPPORT™ at 1-833-ZEPOSIA (1-833-937-6742) and initiates a medical rebate request form

Patient mails the following to the address on the rebate form:

- All receipts
- Explanation of benefits
- Completed rebate request form

The patient receives a check in the mail or direct deposit 1 to 2 weeks after ZEPOSIA 360 Support™ receives all required information.

For additional information and complete terms and conditions for the services listed above, please see www.zeposia.com/terms-conditions.

Please see [full Prescribing Information](#) and [Medication Guide](#) at www.ZEPOSIAhcp.com.

Enroll in ZEPOSIA 360 Support™



Submit electronic Start Form online at **covermymeds®**

Eligible patients who have already completed their baseline assessments with their providers may receive the 28-day Starter Kit up to 4 to 5 days faster compared to faxed enrollment.^a



Call us at **1-833-ZEPOSIA (1-833-937-6742)**

Monday – Friday, 8 AM – 8 PM ET
(translation services available)



Fax Start Form to **1-833-727-7701**



Visit **www.ZEPOSIAhcp.com**

^aCoverMyMeds peer-reviewed data (median values). 6/26/2023 to 5/14/2024.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Bristol Myers Squibb is committed to transparency. For information on the list price of ZEPOSIA as well as information regarding average out-of-pocket costs and assistance programs, please visit <https://www.ZEPOSIA.com/cost>.

ZEPOSIA and ZEPOSIA 360 Support are trademarks of Celgene Corporation, a Bristol Myers Squibb company. CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved.

© 2024 Bristol-Myers Squibb Company.
2084-US-2400698 09/24

